Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition

Phase 2

Completed

Conditions: Chronic Kidney Diseases
Inflammation

Interventions: Biological: Ziltivekimab

First Posted Date: 2019-04-24

Last Posted Date: 2023-08-09

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 264

Registration Number: NCT03926117

Locations: 🇺🇸
Novo Nordisk Investigational Site, Kenosha, Wisconsin, United States

A Research Study in People With Type 2 Diabetes to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine

Phase 2

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin glargine U100
Drug: Insulin icodec

First Posted Date: 2019-04-22

Last Posted Date: 2022-01-18

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 154

Registration Number: NCT03922750

Locations: 🇮🇹
Novo Nordisk Investigational Site, Roma, Italy

A Heart Disease Study of Semaglutide in Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo (semaglutide)
Drug: Semaglutide

First Posted Date: 2019-04-16

Last Posted Date: 2024-11-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 9642

Registration Number: NCT03914326

Locations: 🇦🇷
Centro de Investigaciones Metabólicas, Capital Federal, Argentina
🇦🇷
Centro Diabetologico Cordoba Dr. Waitman, Cordoba, Argentina
🇦🇷
Centro médico privado Cemaic, Córdoba, Argentina

and more 458 locations

A Study to Compare the Uptake Into the Blood of Two Strengths of Somapacitan After Injection Under the Skin in Healthy Subjects

Phase 1

Completed

Conditions: Growth Hormone Deficiency
Healthy Volunteers

Interventions: Drug: somapacitan

First Posted Date: 2019-04-05

Last Posted Date: 2019-08-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 33

Registration Number: NCT03905850

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Effect of Fiasp® in Type 1 Diabetes Treatment

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Fiasp®

First Posted Date: 2019-03-29

Last Posted Date: 2022-04-07

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 178

Registration Number: NCT03895515

Locations: 🇸🇪
Novo Nordisk Investigational Site, Stockholm, Sweden

A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Liraglutide

First Posted Date: 2019-03-25

Last Posted Date: 2021-07-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 839

Registration Number: NCT03888157

Locations: 🇮🇷
Novo Nordisk Investigational Site, Yazd, Iran, Islamic Republic of

A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day

Phase 2

Active, not recruiting

Conditions: Short Stature Children Born Small for Gestational Age (SGA)

Interventions: Drug: Norditropin®
Drug: Somapacitan

First Posted Date: 2019-03-18

Last Posted Date: 2024-12-16

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 62

Registration Number: NCT03878446

Locations: 🇯🇵
Institute of Science Tokyo Hospital, Tokyo, Japan
🇺🇸
Univ of AL at Birmingham_BRM, Birmingham, Alabama, United States
🇺🇸
Goryeb Children's Hospital, Morristown, New Jersey, United States

and more 48 locations

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in United Kingdom, as Part of Local Clinical Practice (SURE UK)

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide

First Posted Date: 2019-03-15

Last Posted Date: 2021-01-19

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 215

Registration Number: NCT03876015

Locations: 🇬🇧
Novo Nordisk Investigational Site, Wellingborough, United Kingdom

Post-marketing Surveillance (Use Result Surveillance) With Refixia®

Conditions: Haemophilia B

Interventions: Drug: Refixia®

First Posted Date: 2019-03-14

Last Posted Date: 2024-08-20

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 20

Registration Number: NCT03875547

Locations: 🇩🇰
Novo Nordisk Investigational Site, Søborg, Denmark
🇯🇵
Nagoya University Hospital_Blood Transfusion, Aichi, Japan
🇯🇵
Chiba University Hospital_Diabetes, Metabolism and Endocrinology, Chiba-shi, Chiba, Japan

and more 14 locations

A Research Study, Looking at How NovoMix® Works in People With Type 2 Diabetes in Local Clinical Practice in Algeria

Withdrawn

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: BIAsp 30

First Posted Date: 2019-03-05

Last Posted Date: 2020-07-20

Lead Sponsor: Novo Nordisk A/S

Registration Number: NCT03862690

Locations: 🇩🇿
Novo Nordisk Investigational Site, Constantine, Algeria

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy